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Glucocorticoids stimulate p21CIP1 in mesangial cells and in anti- Mesangial cell proliferation is an important feature of
GBM glomerulonephritis. mesangial proliferative glomerulonephritis (GN), which
Background. Glucocorticoids are widely used for the treat-
progresses to end-stage renal disease [1, 2]. Mesangialment of glomerulonephritis, but the mechanism of cell cycle
cell proliferation accompanies a wide variety of renalinhibition by glucocorticoids is poorly understood at a molecu-
lar level. diseases, especially proliferative forms of GN. The cell
Methods. The effects of dexamethasone on cell cycle pro- cycle of mesangial cells is under the control of a largegression were examined in rat mesangial cells. To investigate
number of humoral factors that either promote or sup-the mechanisms of cell cycle inhibition by dexamethasone, we
transfected the 22.3 kb p21CIP1 promoter-CAT construct to mes- press mitogenesis and cell proliferation [3, 4]. The precise
angial cells using an electroporation method. We also examined mechanisms that lead to mesangial cell proliferation and
whether glucocorticoids stimulate the expression of p21CIP1 and
cell cycle progression are incompletely understood.inhibit cell proliferation in glomeruli of anti-glomerular base-
The eukaryotic cell cycle is tightly regulated throughment membrane (GBM) glomerulonephritis in rats.
Results. Dexamethasone inhibited 3H-thymidine uptake and a precious balance of positive and negative regulatory
the percentages of S and G2/M phases in rat mesangial cells. components that exert their effects during the first gapDexamethasone stimulated CAT activity of the p21CIP1 pro-
phase (G1) of the cell cycle [5, 6]. The most criticalmoter 4.5-fold. Deletion analysis of the p21CIP1 promoter re-
vealed that the glucocorticoid-responsive region (GRE) is pres- positive-acting components are G1 cyclins (cyclin D and
ent between 21.4 and 21.1 kb upstream of the transcription cyclin E) [6, 7]. Cyclins assemble with cyclin-dependent
initiation site. Dexamethasone inducibility of p21CIP1 promoter
kinase (CDK) and phosphorylate the key physiologicalactivity requires the presence of the C/EBPa DNA binding
substrate, retinoblastoma protein (pRb) [8]. Two distinctsite in the GRE of the p21CIP1 promoter and C/EBPa protein.
Intravenous injection of anti-GBM antibody caused mesangial families of CDK inhibitors have been reported in mam-
proliferation, crescent formation, and proteinuria in rats. Ten malian cells: the kinase-inhibitory protein (Kip) family
days of administration of prednisolone (1 mg/kg/day) reduced
and the inhibitors of the CDK4 (INK4) family. The Kipproteinuria and inhibited mesangial cell proliferation and cres-
cent formation. The glomerular-sieving method revealed that family consists of p27Kip1, p57Kip2, and p21CIP1, all of which
prednisolone increased p21CIP1 expression in glomeruli. have been shown to be potent inhibitors of almost all
Conclusion. These data suggest that the cell cycle arrest of cyclin-CDK enzymes [9–11]. In contrast, the INK4 family,mesangial cells is mediated by a functional link between the
which consists of p16INK4A, p15INK4B, p18INK4C, and p19INK4D,glucocorticoid receptor and the transcriptional control of
p21CIP1 not only in vitro but also in vivo. Our observations specifically interacts with CDK4 and CDK6 [10, 12].
provide new insights into the molecular mechanisms of gluco- The roles of CDK inhibitors in mesangial cell prolifer-
corticoid action in glomerulonephritis.
ation are poorly understood. Recently, Shankland et al
demonstrated that the normal glomerulus has endoge-
nous expression of p27Kip1, which decreases with the initi-
ation of the proliferative response of the mesangial cells
and then normalizes with the resolution of the mesangial
Key words: dexamethasone, cell cycle, mesangial proliferative glomer-
cell proliferation in the Thy-1.1 model of experimentalulonephritis, kinase inhibitory protein family, cyclin-dependent kinase.
mesangial proliferative GN [13]. We reported that the
Received for publication August 23, 2000
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Accepted for publication November 29, 2000 eration of mesangial cells induced by growth-promoting
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Glucocorticoids are widely used for the treatment of treated anti-GBM GN group, prednisolone p.o. was
started on the same day as the anti-GBM antibody injec-GN. Glucocorticoid administration has been reported to
ameliorate mesangial proliferative GN in humans [15, 16]. tion and was continued for 10 days. In the anti-GBM GN
without prednisolone group, saline p.o. was started on theHowever, the mechanism of the antiproliferative effects
of glucocorticoid is poorly understood at a molecular level same day as the anti-GBM antibody injection and was
continued for 10 days. Rats were sacrificed on days 0, 5,in mesangial cells. The functional connection between the
glucocorticoid-regulated transcriptional events and the and 10 (N 5 5 at each time point) after anti-GBM antibody
injection. Immediately after sacrifice, renal biopsies werecell cycle arrest of mesangial cells is not known.
The purpose of this study was to investigate the mecha- taken from each animal for histologic studies, and glomer-
uli were isolated by differential sieving for protein extrac-nisms of glucocorticoid-induced cell cycle arrest in mes-
angial cells and in anti-glomerular basement membrane tion and mRNA detection as described previously [17].
(GBM) GN. To determine whether the inhibitory mech-
Expression vectors and reporter constructsanisms of glucocorticoid on mesangial cell proliferation
are mediated by CDK inhibitors, we investigated the C/EBPa human cDNAs were generous gifts of Dr. H.
Baumann [19]. The p21CIP1 reporter construct used forexpression of CDK inhibitors (p27Kip1, p21CIP1) and activi-
ties of CDK2 and CDK4 in rat mesangial cells and in the CAT assays contained human p21CIP1 promoter from
residues 22280 to 139 cloned upstream of the CAT geneglomeruli of anti-GBM rats treated with glucocorticoids.
We demonstrated that dexamethasone inhibited mesan- (generous gift of Dr. G.L. Firestone and Dr. B. Vogelstein)
[20, 21]. The pCH110 reporter construct contains the SV40gial proliferation mainly via transcriptional up-regula-
tion of p21CIP1. We also examined the effect of dexameth- promoter upstream of the b-galactosidase gene (Phar-
macia Biotechnology Inc., Uppsala, Sweden) [22].asone on a deletion mutant of p21CIP1-promoter-CAT
activity and the effect of cotransfection of CCAAT/
Transient transfection and CAT assayenhancer binding protein (C/EBPa) on p21CIP1-pro-
moter-CAT activity. Finally, we demonstrated that glu- Rat mesangial cells were transfected by the electropor-
ation method. Data are representative of at least fourcocorticoid administration ameliorated cell proliferation
and proteinuria in anti-GBM–induced rat proliferative independent experiments performed in duplicate and
are expressed as “N-fold increase in luciferase activity”GN at least partially by the induction of p21CIP1.
calculated relative to the indicated level of p21CIP1 pro-
moter activity. Plasmid DNAs (10 mg) were transfected
METHODS
by the electroporation method. For experiments per-
Mesangial cell culture formed in exponentially growing cells, CAT activity was
measured 48 hours after transfection using an enzyme-Mesangial cell strains from male Wistar-Kyoto rats
were isolated and characterized as previously reported linked immunosorbent assay (ELISA) kit (Boehringer).
Normalization was achieved by cotransfecting 3.0 mg of[17]. Cells were maintained in RPMI 1640 medium sup-
plemented with 20% fetal bovine serum, 100 U/mL peni- pCH110, a b-galactosidase reporter construct, as an in-
ternal control for the transfection efficiency. For mito-cillin, 100 mg/mL streptomycin, 5 mg/mL of insulin, 5 mg/mL
of transferrin, and 5 ng/mL selenite at 378C in a 5% CO2 gen-stimulated p21CIP1 reporter expression, cells were
stimulated with 20 ng/mL PDGF with or without dexa-incubator. Cells used in experiments were from four to
nine passages. After an initial incubation in medium plus methasone for 24 hours from one day following the trans-
fection. b-Galactosidase activities were measured ac-20% fetal calf serum (FCS) until approximately 80%
confluence, the cells were incubated in medium containing cording to the Promega (Madison, WI, USA) protocol.
dexamethazone (1026 mol/L) plus 20 ng/mL platelet-
Antisense oligonucleotidederived growth factor (PDGF)-BB (Boehinger, Mann-
heim, Germany) for the indicated times. Antisense and scrambled random sequence oligonucle-
otides (oligonucleoside phospharothioates) against p21CIP1
Animal model were synthesized by a DNA synthesizer (Model 8909;
Perseptive Biosystems, Cambridge, MA, USA) andFemale Wistar-Kyoto rats weighing 200 to 250 g were
used in the present study. Experimental proliferative GN purified by an high-performance liquid chromatography
(HPLC). The p21CIP1 antisence oligonucleotide was de-was induced by an intravenous administration of anti-
GBM serum at a dose of 0.25 mL/kg body weight as signed around the start codon of rat p21CIP1, with the
sequence 59-GACATCACCAGGATCGGACAT-39 anddescribed previously [18]. We divided the rats into three
groups: the control group, the anti-GBM GN without the scrambled random sequence control oligonucleotide
p21CIP1 59-TGGATCCGACATGTCAGA-39, have beenprednisolone group, and the anti-GBM GN with predni-
solone group. In the control group, we administered sa- used previously to synthesize oligonucleotides to inter-
fere with p21CIP1 expression in rat vascular smooth muscleline instead of anti-GBM antibody. In the glucocorticoid-
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cells [23]. For the liposome-mediated transfection proce- SSPE and 0.5% SDS, and then exposed to Fuji x-ray
dure, 1026 mol/L oligonucleotide was mixed with cationic film (Fuji Photo Film, Kanagawa, Japan) for three to
liposome using a DOSPER liposomal transfection reagent seven days at 2808C.
transfection kit (Boehringer Mannheim) in serum-free
[3H] thymidine incorporationmedium and incubated for 24 hours for 378C [24]. We
used fluorescein-isothiocyanate-labeled oligonucleotides Mesangial cells were plated in 24-well plates, incu-
(59-GACATCACCAGGATCGGACAT-39) to show the bated in medium containing 20% FCS for 24 hours, and
efficiency of the oligonucleotide transfection. Proliferat- then incubated in medium plus 20% FCS until approxi-
ing mesangial cells were rinsed once in serum-free me- mately 70% confluence. Next, they were incubated in
dium, incubated preliminarily with an oligonucleotide- several mediums containing different concentrations of
liposome solution, and then incubated in medium con- dexamethasone (1025 to 10210 mol/L) plus 20 ng/mL
taining 0.5% serum for 24 hours in humidified incubators PDGF for 24 hours for indicated times. For the last four
at 378C with 5% CO2. The percentage of cells that were hours, the cells were pulsed with 1 mCi [3H] thymidine
positive for uptake of fluorescein isothiocyanate-labeled (Amersham) and counted in Aquasol-2 scintillation
oligonucleotides was determined by ultraviolet fluores- cocktail (NEN Research Products, Boston, MA, USA).
cence microscopy. After incubation with antisense or
scrambled random sequence control oligonucleotides Cell cycle analysis by flow cytometry
(1026 mol/L) for 24 hours, mesangial cells were incubated Mesangial cells were cultured in a 75 cm2 flask. Next,
with 1026 mol/L dexamethasone. after an initial incubation in RPMI 1640 medium plus
20% FCS until approximately 80% confluence, the cellsWestern blot analysis
were incubated in medium with or without dexametha-
The proteins were extracted from mesangial cells or iso- sone (1026 mol/L) plus 20 ng/mL PDGF for 24 hours. The
lated glomeruli using an extraction buffer containing cells were stained with propidium iodide and analyzed by
50 mmol/L b-glycerophosphate, pH 7.3, 1.5 mmol/L flow cytometry using a Coulter flow cytometer (Coulter
EGTA, 0.1 mmol/L Na3VO4, 1 mmol/L dithiothreitol Corporation, Hialeah, FL, USA), and the percentages
(DTT), 10 mg/mL leupeptine, 10 mg/mL aprotinine, of the cells in the G1, S, and G2/M phases were deter-
2 mg/mL pepstatin A, and 1 mmol/L benzamidine as mined [26].
described previously [25]. Fifty micrograms of protein
were resolved in sodium dodecyl sulfate-polyacrylamide Immunoprecipitation and CDK4, CDK2 kinase assay
gel electrophoresis (SDS-PAGE), and the proteins were
Immune complex kinase assay was performed usingthen transferred to an Immobilon P membrane (Daiichi-
essentially the same methods described by Matsushimekagaku, Tokyo, Japan). To detect p27Kip1, p21CIP1, cyclin
et al [27]. Cell lysates of mesangial cells and isolatedD1, cyclin E, CDK2, and CDK4, the membrane was in-
glomeruli were incubated for two hours at 48C with 20 mLcubated with antibodies (Santa Cruz Biotechnology,
of protein G-plus agarose (Oncogene Science, Union-Santa Cruz, CA, USA) at a dilution of 1:1000 in TBS
dale, NY, USA) and 10 mL of anti-rat-CDK4 antibody orcontaining 0.5% Tween 20 for two hours at 378C and
anti-rat-CDK2 antibody (Santa Cruz Biochemical Inc.),then visualized using the ECL chemiluminescence system
and immune complexes were recovered by centrifuga-(Amersham, Little Chalfort, UK). Films were scanned
tion. Immunoprecipitated proteins were suspended inusing an Epson scanner (Nagano, Japan). Signals on West-
30 mL of kinase buffer (50 mmol/L HEPES, pH 7.5,ern blots were quantitated by densitometry using an image
10 mmol/L MgCl2, 1 mmol/L dithiothreitol) containinganalysis software application (NIH Image 1.47).
substrate (0.2 mg of soluble glutathione S-transferase-
pRb fusion protein for the CDK4 kinase assay, and his-Northern blot analysis
tone H1; Boehringer Mannheim for the CDK2 assay)The mRNA was extracted from isolated glomeruli using
and 2.5 mmol/L EGTA, 10 mmol/L b-glycerophosphate,TRI-REAGENTe (Life Technologies, Gaithersburg,
1 mmol/L NaF, 20 mmol/L ATP, and 10 mCi of [g-32P]MD, USA). Twenty micrograms of total RNA samples
ATP (6000 Ci/mmol; NEN, DuPont, Boston, MA, USA).were separated on 1% agarose-formaldehyde-MOPS
After incubation for 30 minutes at 308C with occasionalgels and transferred to Hybond-N hybridization mem-
mixing, the samples were boiled in polyacrylamide gelbranes (Amersham). A series of 2.7 kb full-length murine
sample buffer containing SDS and separated by electro-p21CIP1 cDNAs [11] was labeled by the random priming
phoresis. Phosphorylated proteins were visualized by au-method and used as probes for Northern hybridization.
toradiography.Following hybridization, the membranes were washed
Immunoprecipitated protein was resolved in SDS-twice for five minutes at room temperature in 5 3 SSPE
PAGE and analyzed by Western blotting with p21CIP1,and 0.5% SDS, twice at 378C for 15 minutes in 1 3 SSPE
and 0.5% SDS, once at 378C for 15 minutes in 0.1 3 CDK2, and CDK4 antibody.
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Fig. 1. Effect of dexamethasone on [3H]-thy-
midine incorporation and cell cycle progres-
sion in rat mesangial cells. (A) Rat mesangial
cells were treated with (1026 to 1029 mol/L)
or without dexamethasone for 24 hours, with
pulse radio labeling for the last four hours with
[3H]thymidine. Radioactivity of cell lysate was
quantitated by scintillation counting. (B) Rat
mesangial cells were treated with (1026 mol/L)
or without dexamethasone for 24 hours and
then stained with propidium iodide solution.
The DNA content of cell nuclei was per-
formed by flow cytometry.
Histologic examination Effect of dexamethasone on CDK2 and CDK4
activities and protein levels of p21CIP1, p27KIP1, cyclinRenal tissues obtained from control, saline-treated, or
D1, cyclin E, CDK2, and CDK4 in rat mesangial cellsprednisolone-treated anti-GBN GN rats were fixed in
formalin overnight and then dehydrated and paraffin To determine the inhibitory mechanisms of dexameth-
embedded. Thin sections were examined with periodic asone on cell cycle progression, we examined the effects
acid-Schiff staining as described previously [28]. of dexamethasone on protein expression of the following
G1/S-regulated genes: p21CIP1, p27KIP1, cyclin D1, cyclin
Statistical analysis E, CDK2, and CDK4. Rat mesangial cells were treated
The results were given as means 6 SEM. The differ- with or without (1026 mol/L) dexamethasone for 24 hours
ences were tested using analysis of variance. P , 0.05 in the presence of 20 mg/mL PDGF. Rat mesangial cells
was considered significant. treated without dexamethasone or PDGF served as the
control. Twenty micrograms of cell lysate protein were
used for Western blot analysis. The protein expression
RESULTS
of p21CIP1, p27KIP1, cyclin D1, cyclin E, CDK2, and CDK4
Dexamethasone inhibited [3H]-thymidine was determined by Western blot analysis using specific
incorporation and cell cycle progression antibodies. Figure 2A demonstrates that dexamethasone
induced by PDGF in rat mesangial cells significantly increased the expression of p21CIP1 but not
the expressions of p27KIP1, cyclin D1, cyclin E, CDK2,To determine the effects of dexamethasone on cell cycle
progression, dexamethasone was added to asynchronous and CDK4.
To determine the effects of dexamethasone on themesangial cells. Various concentrations of dexametha-
sone were added to mediums containing 20 ng/mL PDGF CDK activities, CDK2 and CDK4 activities were mea-
sured in PDGF-stimulated mesangial cells with or with-for 24 hours, and [3H]-thymidine incorporation was mea-
sured. As shown in Figure 1A, PDGF-stimulated [3H]- out dexamethasone (1026 mol/L). Equal amounts of cell
extract (1 mg) were immunoprecipitated with antibodiesthymidine incorporation is inhibited dose dependently
in the presence of dexamethasone. Cell cycle analysis by against CDK2 or CDK4. The kinase activities of the
immunoprecipitates were assayed using histone H1 forflow cytometry revealed that dexamethasone (1026 mol/L)
reduced the percentage of PDGF-stimulated increments CDK2 and GST-Rb for CDK4. Figure 2B shows that
the kinase activities associated with CDK2 and CDK4of S phase and G2/M phase (Fig. 1B).
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Fig. 2. Effect of dexamethasone on CDK2
and CDK4 kinase activities and protein levels
of p21CIP1, p27KIP1, cyclin D1, cyclin E, CDK2,
and CDK4 in rat mesangial cells. (A) Western
blot analysis. Rat mesangial cells were treated
with or without (1026 mol/L) dexamethazone
(Dex) in the presence or absence of 20 ng/mL
PDGF for 24 hours. Twenty micrograms of
cell lysate protein were used for Western blot
analysis. The protein production of p21CIP1,
p27KIP1, cyclin D1, cyclin E, CDK2, and CDK4
was determined by Western blot analysis using
specific antibodies. (B) Kinase assay. CDK2
and CDK4 activities were measured in PDGF-
stimulated mesangial cells with or without Dex
(1026 mol/L). Equal amounts of cell extract
(1 mg) were immunoprecipitated with anti-
bodies against CDK2 or CDK4. The kinase
activities of the immunoprecipitates were as-
sayed using histone H1 for CDK2 and GST-
Rb for CDK4. Western blot of p21CIP1 was per-
formed after immunoprecipitation with CDK2
or CDK4.
Fig. 3. Deletion analysis of the p21CIP1 pro-
moter defines a 297 bp glucocorticoid-respon-
sive element (GRE). Rat mesangial cells were
transiently transfected with a series of p21CIP1-
CAT reporter plasmids that contains indi-
cated 59 deletions of the p21CIP1 promoter and
b-galactosidase plasmid. Cells were treated
with (1026 mol/L) or without dexamethasone
for 24 hours, and then the CAT-specific activ-
ity was determined using ELISA CAT assay
kits. The CAT activity was normalized by
b-galactosidase activity. The reported values
are an average of four independent experi-
ments (mean 6 SEM). *P , 0.05 vs. CAT
activity of 22280 plasmid.
were up-regulated in the presence of PDGF and re- Deletion analysis of the p21CIP1 promoter defines a
297 bp glucocorticoid-responsive regionpressed in dexamethazone-treated cells. To confirm
whether or not the decrease of CDK2 and CDK4 activity To determine which region within the p21CIP1-pro-
was mediated by increment of p21CIP1 level, we performed moter was responsible for the glucocorticoid-mediated
Western blot analysis of p21CIP1 after immunoprecipita- transcriptional activation, rat mesangial cells were tran-
tion with CDK2 or CDK4. The level of p21CIP1 associated siently transfected with a series of p21CIP1-CAT reporter
with CDK2 was increased in the dexamethasone-treated plasmids that contain indicated 59 deletions of the p21CIP1
mesangial cells (Fig. 2B). This suggested that the incre- promoter plasmid (Fig. 3). Mesangial cells were treated
ment of p21CIP1 mediated the decrease of CDK2 kinase with or without (1026 mol/L) dexamethasone for 24
activity. The level of p21CIP1 associated with CDK4 was hours, and CAT-specific activity was determined using
also increased in the dexamethasone-treated mesangial ELISA CAT assay kits. The CAT activity was normal-
cell (Fig. 2B). This suggested that the increment of p21CIP1 ized by b-galactosidase activity. Dexamethasone stimu-
lated the transcriptional activity of p21CIP1-CAT constructsmediated the decrease of CDK4 kinase activity.
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Fig. 5. Mutation of the C/EBPa DNA binding site reduced dexametha-
sone inducibility of p21CIP1 promoter activity. Cotransfection of C/EBPa
construct significantly increased dexamethasone-induced p21CIP1 pro-
moter activity. Rat mesangial cells were transiently cotransfected with
a wild-type p21CIP1 promoter (h) or mutated C/EBPa-CAT reporter
( ) plasmid, a C/EBPa expression plasmid, and a b-galactosidase plas-
mid. Cells were treated with or without (1026 mol/L) dexamethasone
for 24 hours, and CAT-specific activity was determined using ELISA-
CAT assay kits. The CAT activity was normalized by b-galactosidase
Fig. 4. Time course of dexamethasone effects on protein levels of activity. The reported values are an average of four independent experi-
p21CIP1 and C/EBPa in rat mesangial cells. Rat mesangial cells were ments (mean 6 SEM). *P , 0.05 vs. CAT activity of wild-type p21CIP1
treated with or without (1026 mol/L) dexamethasone for indicated times. promoter plasmid without dexamethasone or cotransfection of a C/EBPa
Twenty micrograms of cell lysate protein were used for Western analy- expression plasmid.
sis. The protein productions of p21CIP1 and C/EBPa were determined
by Western blot analysis using specific antibodies. Band intensities of
p21CIP1 were obtained by densitometry of immunoblots, and expression
is presented as the fraction of expression in control (0 hour). Results
are means 6 SEM of four independent experiments. gial cells. Cells were treated with or without (1026 mol/L)
dexamethasone for indicated times. As shown in Figure 4,
the protein level of C/EBPa was augmented as early as
three hours after the addition of dexamethasone, whilecontaining the three largest p21CIP1 promoter regions with
p21CIP1 was augmented more slowly, and did not reachdeletions ending at 22280, 21846, and 21435 bp. Dexa-
significant levels until 12 to 24 hours after the additionmethasone inducibility of the p21 promoter was lost in
of dexamethasone. These results suggested that C/EBPadeletions beyond 21139 bp. These results indicated that
protein might be important for dexamethasone to inducethe promoter sequence between nucleotides 21435 and
p21CIP1 promoter activity.21139 of the p21CIP1 promoter was the glucocorticoid-
Next, we performed a mutation analysis of the C/EBParesponsive region (GRE) in rat mesangial cells.
DNA binding site in the stimulation of dexamethasone-
induced p21CIP1 transcription. Sequence analysis of theRequirement of C/EBPa expression for the
transcriptional stimulation of p21CIP1 promoter promoter region of p21CIP1 revealed no canonical gluco-
activity by dexamethasone in rat mesangial cells corticoid-responsive elements, but the promoter did con-
tain a putative C/EBP DNA binding site between nucleo-The previous studies by Cram et al demonstrated first
tides 21270 and 21256, as described previously [20]. Tothat the expression of C/EBPa transcription factor was
test whether the C/EBP DNA-binding site in the p21CIP1required for the induction of p21CIP1 protein in hepatoma
promoter contributed to the glucocorticoid-regulatedcells, and second that a canonical C/EBPa DNA binding
transcriptional activity in rat mesangial cells, the ATCCsite was present at 21270 bp in the p21CIP1 promoter [20].
TCTGCAATTT wild-type C/EBP DNA binding site inIn our current study, therefore, we examined the require-
p21CIP1 promoter was mutated to ATCCTCCCATGGTTment of C/EBPa expression for induction of p21CIP1. At
in order to eliminate the key nucleotides required forfirst, we examined the time course of dexamethasone ef-
fects on protein levels of p21CIP1 and C/EBPa in rat mesan- transcription factor bindings in the manner described
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Fig. 6. Glucocorticoid administration at least partially ameliorated cell proliferation and proteinuria in anti-GBM antibody-induced proliferative
GN via the induction of p21CIP1. Wistar-Kyoto rats were divided into three groups: the control group, the anti-GBM GN without prednisolone
group, and the anti-GBM GN with prednisolone group. In the anti-GBM GN with or without prednisolone group, we administered prednisolone
(1 mg/kg/day) or saline for 5 or 10 days just after anti-GBM antibody injection to rats. In control rats, saline was administered instead of anti-
GBM antibody. (A) Histologic examinations of periodic acid-Schiff staining (3400) at 10 days are shown: control group, anti-GBM GN without
prednisolone group, and anti-GBM GN with prednisolone group. (B) Levels of proteinuria of the control group, anti-GBM GN without prednisolone
group, and anti-GBM GN with prednisolone group. Administration of prednisolone significantly ameliorated proteinuria of anti-GBM GN at 5
and 10 days. Results are means 6 SEM of five independent experiments (*P , 0.05). (C ) Western blot analysis and Northern blot analysis from
glomeruli of control group, anti-GBM GN without prednisolone group, and anti-GBM GN with prednisolone group. The level of p21CIP1 protein
and mRNA expression increased in glomeruli of anti-GBM GN with prednisolone group compared with that of anti-GBM GN without prednisolone
group, suggesting a transcriptional increment of p21CIP1 expression in vivo. (D) The protein levels of CDK2 and CDK4 were the same in the
glomeruli of the anti-GBM GN with prednisolone group compared with that of the anti-GBM GN without prednisolone group. (E) CDK2 and
CDK4 activities were measured in isolated glomeruli of control group, anti-GBM GN without prednisolone group, and anti-GBM GN with
prednisolone group. Equal amounts of cell extract (1 mg) were immunoprecipitated with antibodies against CDK2 and CDK4. The kinase
activities of the immunoprecipitates were assayed using histone H1 for CDK2 and GST-Rb for CDK4. Western blot analysis of p21CIP1 after
immunoprecipitation with CDK2 or CDK4 revealed that protein levels of p21CIP1 associated with CDK2 and CDK4 were increased in the glomeruli
of anti-GBM GN with prednisolone group.
previously for hepatoma cells [20]. These p21CIP1 pro- site in rat mesangial cells, whereas the reporter plasmid
containing the wild-type C/EBP DNA-binding site wasmoter fragments containing either the wild-type or the
C/EBP DNA-binding site mutation were linked up- responsive to dexamethasone. Transient expression of
C/EBPa increased the CAT activity significantly in thestream of the thymidine kinase (tk) minimal promoter
sequence driving the bacterial CAT gene [20]. As shown wild-type p21CIP1 promoter fragment but not in the cells
transfected with the reporter plasmid mutated in thein Figure 5, dexamethasone failed to induce CAT activity
in the reporter-plasmid–mutated C/EBP DNA binding C/EDPa binding site.
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Fig. 6. (Continued)
Glucocorticoid administration ameliorated prednisolone group accumulated increased amounts of
p21CIP1 protein and mRNA compared with glomeruli ofcell proliferation and proteinuria in anti-GBM
the anti-GBM GN without prednisolone group (Fig. 6C).antibody-induced rat proliferative GN at least
In contrast, Western blot analysis of CDK2 and CDK4partially via the induction of p21CIP1
with total cell lysate of isolated glomeruli showed noTo determine the inhibitory effect of glucocorticoid
changes in the protein levels of CDK2 and CDK4 in thein mesangial cell proliferation in vivo, we established
glomeruli of the anti-GBM GN with prednisolone groupthree groups of rats: a control group, an anti-GBM GN
(Fig. 6D).without prednisolone (saline-treated) group, and an anti-
To determine the effects of prednisolone on the CDKGBM GN with prednisolone group. In the anti-GBM
activities in glomeruli of the anti-GBM antibody-inducedGN with prednisolone group, prednisolone (1 mg/kg/
GN group, an immunocomplex kinase assay was per-day) was administered just after the anti-GBM antibody
formed from glomeruli of the control group, anti-GBM
injection to rats for 5 or 10 consecutive days. As shown GN without prednisolone group, and anti-GBM GN with
in Figure 6A, glomeruli of the anti-GBM GN without prednisolone group. Kinase activities of CDK2 and
prednisolone group showed a marked increase in mesan- CDK4 of glomeruli from the anti-GBM GN with predni-
gial proliferation and crescent formation on day 10 com- solone group were significantly decreased compared with
pared with the control group. In contrast, the glomeruli that of anti-GBM GN without prednisolone group, as
of the anti-GBM GN with prednisolone group showed shown in Figure 6E. Western blot analysis of p21CIP1 after
a significant amelioration in mesangial proliferation and immunoprecipitation with CDK2 or CDK4 revealed that
crescent formation compared with the glomeruli of the protein levels of p21CIP1 associated with CDK2 and CDK4
anti-GBM GN without prednisolone group on day 10 were increased in the glomeruli of anti-GBM GN with
(Fig. 6A). The level of proteinuria in the anti-GBM GN prednisolone group.
with prednisolone group was ameliorated compared with
Effect of p21CIP1 antisense and scrambled randomthe level of the anti-GBM GN without prednisolone
sequence phosphorothioate oligonucleotide on p21CIP1group at both 5 and 10 days (Fig. 6B).
protein expression and dexamethasone-induced-Furthermore, we performed Western blot analysis,
inhibition of [3H]-thymidine incorporation in ratNorthern blot analysis, and CDK2 and CDK4 assays
mesangial cellsfrom isolated glomeruli in the control group, anti-GBM
GN without prednisolone group, and anti-GBM GN with To test whether interference with p21CIP1 expression
using an antisense oligonucleotide approach influencedprednisolone group. Glomeruli of anti-GBM GN with
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dexamethasone-induced cell cycle arrest, protein synthe- gial cells. Fourth, our previous report demonstrated that
overexpression of p21CIP1 caused cell cycle arrest in ratsis and [3H]-thymidine incorporation were measured in
rat mesangial cells transiently transfected with 1026 mol/L mesangial cells [14].
To our knowledge, this is the first report showing thatof p21CIP1 antisense and scrambled random sequence
phosphorothioate oligonucleotides. At first, we used prednisolone administration increases p21CIP1 protein
levels in the glomerulus in vivo. Furthermore, this reportfluorescein-isothiocyanate-labeled oligonucleotides to
show the efficiency of the oligonucleotide transfection. is the first to propose a mechanism of glucocorticoid
inhibition of mesangial cell proliferation and proteinuriaWe observed that oligonucleotides were taken up and
concentrated in the nuclei of 85 to 90% of cells. in proliferative GN rats. Our data from immunoblot,
Northern blot, and immunohistological analyses clearlyAs shown in Figure 7 (lower panel), transfection with
p21CIP1 antisense phosphorothioate oligonucleotide sig- demonstrate that glucocorticoid increases p21CIP1 mRNA
and protein levels in glomeruli of rat anti-GBM GN.nificantly inhibited dexamethasone-induced p21CIP1 pro-
tein expression in rat mesangial cells. p21CIP1 protein The evidence from the present in vitro and in vivo experi-
ments strongly suggests that glucocorticoid at least partlyexpression was inhibited by p21CIP1 antisense phosphoro-
thioate oligonucleotide but not by p21CIP1 scrambled ran- inhibited mesangial proliferation via a transcriptional
induction of p21CIP1 in anti-GBM GN. However, in ourdom sequence phosphorothioate oligonucleotide. p21CIP1
antisense oligonucleotide abolished the inhibitory effects experiments, p21CIP1 actually was demonstrated only in
isolated glomeruli and not in mesangial cells in vivoof dexamethasone on PDGF-stimulated [3H]-thymidine
incorporation in rat mesangial cells (Fig. 7, upper panel). (Fig. 6). It is possible that prednisolone might induce
p21CIP1 in other glomerular cells, particularly in the epi-
thelial cells.
DISCUSSION
Many glomerular diseases are characterized by mesan-
In the present study, we demonstrate that dexametha- gial cell proliferation and accumulation of mesangial ex-
sone significantly increased the protein expression and tracellular matrix [1, 2]. The mechanisms of regulation
promoter activity of p21CIP1 in rat mesangial cells. Dele- of the mesangial cell cycle are largely unknown. Shank-
tion analysis revealed that dexamethasone inducibility land et al recently showed that the normal glomerulus
of the p21CIP1 promoter was present between 21435 and has a high endogenous expression of p27Kip1 that de-
21139 bp. Dexamethasone inducibility of p21CIP1 pro- creases with the initiation of the mesangial cells’ prolifer-
moter activity required the presence of the C/EBPa ative response and then normalizes with the resolution
DNA binding site in the p21CIP1 promoter region and of the mesangial cell proliferation in the Thy-1.1 model
C/EBPa protein. We also demonstrated that glucocorti- of experimental mesangial proliferative GN [13]. Fur-
coid administration at least partially ameliorated cell thermore, they found that p21CIP1 has low levels of expres-
proliferation and proteinuria in anti-GBM antibody- sion in the normal rat glomerulus [13]. Recently, in our
induced rat proliferative GN via the induction of p21CIP1. own investigation of the mechanisms of the cell cycle
Glucocorticoid has been widely used as a therapy for regulation of rat mesangial cells, we demonstrated that
mesangial proliferative GN [15, 16]. Glucocorticoid is FCS and PDGF stimulated CDK2 and CDK4 kinase
known to inhibit or stimulate the in vivo and in vitro activity and that these stimulatory activities were inhib-
growth of many types of normal and transformed cells ited by overexpressions of CDK inhibitor (p16INK4 and
[29–31]. However, the molecular mechanisms of the anti- p21CIP1) [14]. These studies indicated that mesangial cell
mitogenic effects of glucocorticoid in mesangial prolifer- proliferation is regulated by a precise balance of CDK
ative disease have not been clarified. This report is the kinase and CDK inhibitors. The present study demon-
first, to our knowledge, to demonstrate the involvement strates that among these CDK inhibitors, p21CIP1 plays a
of p21CIP1 in the inhibitory effects of dexamethasone on key role in the mesangial cell cycle not only in vitro but
mesangial cell proliferation both in vitro and in vivo. also in vivo. Furthermore, other recent studies demon-
We believe that p21CIP1 may play a critical role in the strated that p21CIP1 induces cell cycle-independent effects
glucocorticoid-induced cell cycle arrest in mesangial cells such as cell differentiation and apoptosis in myocytes
for the following reasons. First, the protein level of and vascular smooth muscle cells [23, 32, 33]. The effects
p21CIP1 was increased, and cell cycle progression was in- may influence mesangial cell transformation and anti-
hibited in the presence of glucocorticoid. Second, these inflammatory mechanisms in the rat GN model.
inhibitory effects were accompanied by a reduction of This study demonstrates that dexamethasone stimu-
CDK2 and CDK4 kinase activities, whereas the protein lates the promoter activity of p21CIP1 and increases the
levels of CDK2, CDK4, p27Kip1, cyclin D, and cyclin E p21CIP1 protein expression in mesangial cells. We define
were not changed in the presence of dexamethasone. the GRE as bases 21435 to 21139 of the p21CIP1 pro-
Third, antisense oligonucleotide for p21CIP1 reversed the moter sequence. This result is in agreement with the
Firestone group’s reports on hepatoma cell lines [20, 34].antiproliferative glucocorticoid action in cultured mesan-
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tion of C/EBPa in dexamethasone-induced p21CIP1 up-
regulation should be analyzed in future studies.
In conclusion, the present study provides new insights
into the pathophysiological role of glucocorticoid in pro-
liferative GN. These data indicate a functional link be-
tween the glucocorticoid receptor signaling pathway and
the transcriptional control of p21CIP1 that mediates cell
cycle arrest, as well as an enhancement of this linkage
by C/EBPa, in mesangial cells in vitro and in rat prolifer-
ative GN.
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